secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001558370-23-018691
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Phase 2b zunsemetinib fails endpoints; ATI-450 program discontinued
---------------------------------------------------------------------------

- Study of oral MK2 inhibitor zunsemetinib (20mg or 50mg BID) in 251 RA patients did not meet primary endpoint ACR20 at week 12.
- No differentiation from placebo on secondary endpoints (ACR50, ACR70, DAS28-CRP); no meaningful safety findings.
- Aclaris discontinues ATI-450 development; halts enrollment in Phase 2a psoriatic arthritis trial.
- Phase 2b results for ATI-1777 (topical JAK1/3) in atopic dermatitis expected year-end 2023; Phase 2 for ATI-2138 planned early 2024.
- Cash, cash equivalents and marketable securities of $187.0M as of Sep 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023018691/0001558370-23-018691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023018691/acrs-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer